Novo Nordisk and Amazon Web Services (AWS) have established a strategic partnership to accelerate drug discovery using artificial intelligence and cloud technology.
The companies opened a co-innovation hub in London where engineers and scientists will collaborate directly. This initiative aims to shorten the timeline from identifying a drug target to administering the first human dose.
Novo Nordisk will utilize AWS AI services, including Amazon Bio Discovery and Amazon Bedrock, to identify new drug targets and design therapies. The partnership also focuses on enhancing clinical trial design. This collaboration expands a multi-year relationship and follows a broader industry trend of pharmaceutical giants adopting AI for research and development.